Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. Changing trends in real-world evidence
  2. AAAAI/WAO 2018: Stallergenes Greer presents US paediatric safety data for Oralair
  3. Aimmune’s AR101 shows outstanding efficacy in Phase III Trial—now it’s time to improve safety
  4. Verastem’s duvelisib seeks FDA approval for relapsed or refractory CLL
  5. Continued growth for GLP-1 receptor agonists and SGLT-2 inhibitors in 2017

Latest Content

Sanofi seeks EMA approval for asthma drug Dupixent

The European Medicines Agency (EMA) has accepted Sanofi’s application to review its drug Dupixent (dupilumab) as an add-on maintenance treatment in patients aged 12 years and older with inadequately controlled moderate-to-severe asthma.

Is IL-23 the new hot target for Psoriasis?

On March 21, the FDA approved Sun Pharma’s Ilumya (tildrakizumab) for the treatment of adults with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. Ilumya marks the second interleukin-23 (IL-23) inhibitor to gain FDA approval within the past year, following the approval of J&J’s Tremfya (guselkumab) in July 2017.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top